Flag­ship merges two star­tups to build a $220M Reper­toire of T cell tech, ther­a­pies

Soon af­ter John Cox took over as CEO at Torque Ther­a­peu­tics, he reached out to Jose‑Car­los Gutiér­rez‑Ramos.

Gutiér­rez‑Ramos, who left Syn­log­ic in 2018 to join Flag­ship Pi­o­neer­ing, was lead­ing a start­up in its port­fo­lio named Co­gen Im­mune Med­i­cines. The team there was hon­ing tech­nolo­gies to de­ci­pher the im­mune synapse around T cells — tech­nolo­gies that, Cox fig­ured, could help char­ac­ter­ize the T cells and pep­tides in­volved in Torque’s can­cer ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER